Gillian Vandekerkhove

机构：BC Cancer Agency, University of British Columbia, The Prostate Centre · ORCID：0000-0001-5606-0908

发表论文 208 篇 · 总被引 2283 次 · h-index 19

代表论文

• Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer (2025 · Annals of Oncology · 被引 2)
• Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer (2026 · Nature Communications · 被引 1)
• Abstract 5107: Feasibility and interim results from the prospective international LS-URO study: Urine tumor DNA-based screening for urothelial cancer in Lynch syndrome carriers (2026 · Cancer Research)
• ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial. (2026 · Journal of Clinical Oncology)
• Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis (2025 · European Urology Oncology)
• Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer (2025)